Thursday, January 04, 2018 -- An international team of researchers has developed a novel compound that successfully inhibits growth of melanoma cells by targeting specific epigenetic modifying proteins in these cells.
Friday, January 05, 2018 -- Hussein A. Tawbi, MD, discusses the considerations he makes when choosing between immunotherapy and targeted therapy for patients with melanoma and how long-term targeted therapy data can influence treatment decisions.
Thursday, January 04, 2018 -- Nivolumab (Opdivo) has received FDA approval for the adjuvant treatment of patients with completely resected melanoma with lymph node involvement or metastatic disease.
Thursday, January 04, 2018 -- Actively targeting specific genetic mutations that give rise to cancer is challenging enough for researchers and drug manufacturers, but trying to target changes that arise due to differential expression and regulation of gene products takes the concept of challenging to a new level. Yet, that is exactly what a team of researchers from Boston University School of Medicine, Johns Hopkins University, Universit à di Pavia, Harvard Medical School, and the University of Leicester has just accomplished using a newly developed compound that successfully inhibits the growth of melanoma cells by targeting specific epigenetic-modifying proteins. Findings from the new study—published today in Nature Communications in an article entitled “ Targeting the CoREST Complex with Dual Histone Deacetylase and Demethylase Inhibitors
Thursday, January 04, 2018 -- Anti–PD-1–based immunotherapy has had a major impact on cancer treatment but has only benefited a subset of patients. Among the variables that could contribute to interpatient heterogeneity is differential composition of the patients’ microbiome, which has been shown to affect antitumor immunity and immunotherapy efficacy in preclinical mouse models. We analyzed baseline stool samples from metastatic melanoma patients before immunotherapy treatment, through an integration of 16S ribosomal RNA gene sequencing, metagenomic shotgun sequencing, and quantitative polymerase chain reaction for selected bacteria. A significant association was observed between commensal microbial composition and clinical response. Bacterial species more abundant in responders included Bifidobacterium longum, Collinsella aerofaciens, and Enterococcus faecium. Reconstitution of germ-free mice with fecal material from responding patients could lead
Thursday, January 04, 2018 -- Preclinical mouse models suggest that the gut microbiome modulates tumor response to checkpoint blockade immunotherapy; however, this has not been well-characterized in human cancer patients. Here we examined the oral and gut microbiome of melanoma patients undergoing anti–programmed cell death 1 protein (PD-1) immunotherapy (n = 112). Significant differences were observed in the diversity and composition of the patient gut microbiome of responders versus nonresponders. Analysis of patient fecal microbiome samples (n = 43, 30 responders, 13 nonresponders) showed significantly higher alpha diversity (P < 0.01) and relative abundance of bacteria of the Ruminococcaceae family (P < 0.01) in responding patients. Metagenomic studies revealed functional differences in gut bacteria in responders, including enrichment of anabolic pathways. Immune profiling suggested
Tuesday, January 02, 2018 -- Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.
Thursday, January 04, 2018 -- Oslo, Norway, 4 January 2018 - Targovax ASA (OSE: TRVX), a clinical stage company focused on developing immuno-oncology therapies to target solid tumors, today announces immune activation data in the first four patients...